JP2001500858A - 核酸粒子の送達 - Google Patents
核酸粒子の送達Info
- Publication number
- JP2001500858A JP2001500858A JP10513388A JP51338898A JP2001500858A JP 2001500858 A JP2001500858 A JP 2001500858A JP 10513388 A JP10513388 A JP 10513388A JP 51338898 A JP51338898 A JP 51338898A JP 2001500858 A JP2001500858 A JP 2001500858A
- Authority
- JP
- Japan
- Prior art keywords
- particles
- nucleic acid
- skin
- particle
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.治療に用いるための、核酸分子を含み、金属キャリアを含まない、粒子。 2.治療に用いるための、核酸分子からなる、またはその重量が核酸分子を主に 含む、粒子。 3.平均サイズが、皮膚または粘膜組織中の標的細胞のサイズと少なくとも同じ 大きさである、請求項1または2に記載の粒子。 4.平均サイズが10〜250μmである、請求項1〜3のいずれかに記載の粒子。 5.キャリアを含む、請求項1〜4のいずれかに記載の粒子。 6.前記キャリアがトレハロースを含む、請求項5に記載の粒子。 7.前記核酸分子が、免疫原をコードするヌクレオチド配列を含む、請求項1〜 6のいずれかに記載の粒子。 8.皮膚または粘膜組織への針を用いない投与による治療に用いるための、金属 キャリアを含まない医薬の製造のための、核酸分子を含む粒子の使用。 9.前記粒子が、請求項2〜7のいずれかに規定される、請求項8に記載の使用 。 10.前記核酸分子が、標的細胞ゲノムから欠損または欠失しているタンパク質 をコードする遺伝子を含む、請求項8または9に記載の使用。 11.送達されるべき活性成分として、請求項1〜7のいずれかで規定される粒 子を含む、針のないシリンジ。 12.2〜10kg/秒/mの間の運動量密度で粒子を送達するように適合された、請 求項11に記載の針のないシリンジ。 13.皮膚または粘膜組織中の標的細胞に、核酸分子を含む粒子を送達する方法 であって、該粒子が、針のないシリンジによって該皮膚または粘膜組織に投与さ れ、かつ金属キャリアを含まない、方法。 14.前記粒子が、前記標的細胞のサイズと等しいか、またはそれより大きい平 均サイズを有する、請求項13に記載の方法。 15.前記粒子が、主に約10〜250μmの範囲にある平均サイズを有する、請求 項13に記載の方法。 16.前記粒子が、2〜10kg/秒/mの間の運動量密度で、前記皮膚または粘膜組 織粒子に投与される、請求項13〜15のいずれかに記載の方法。 17.前記粒子が、表皮組織中の標的細胞に送達される、請求項13〜16のい ずれかに記載の方法。 18.前記粒子が、皮膚組織の基底層中の標的細胞に送達される、請求項13〜 16のいずれかに記載の方法。 19.前記粒子が、核酸分子およびキャリア材料を含む、請求項13〜18に記 載の方法。 20.前記キャリア材料がトレハロースを含む、請求項19に記載の方法。 21.前記粒子が、インビボで前記皮膚または粘膜組織に送達される、請求項1 3〜20のいずれかに記載の方法。 22.前記粒子が、エクスビボで前記皮膚または粘膜組織に送達される、請求項 13〜20のいずれかに記載の方法。 23.前記核酸分子が、前記標的細胞ゲノムから欠損または欠失しているタンパ ク質をコードする遺伝子を含む、請求項13〜22のいずれかに記載の方法。 24.前記核酸分子が、免疫原をコードするヌクレオチド配列を含む、請求項1 3〜22のいずれか1項に記載の方法。 25.針のないシリンジによる皮膚または粘膜組織への投与に適切な粒子状核酸 組成物であって、該組成物は金属キャリアを含まない、組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9619002.0A GB9619002D0 (en) | 1996-09-11 | 1996-09-11 | Particle delivery |
GB9619002.0 | 1996-09-11 | ||
PCT/GB1997/002478 WO1998010750A2 (en) | 1996-09-11 | 1997-09-11 | Nucleic acid particle delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001500858A true JP2001500858A (ja) | 2001-01-23 |
JP2001500858A5 JP2001500858A5 (ja) | 2005-05-12 |
Family
ID=10799793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10513388A Ceased JP2001500858A (ja) | 1996-09-11 | 1997-09-11 | 核酸粒子の送達 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0928190B1 (ja) |
JP (1) | JP2001500858A (ja) |
AU (1) | AU4307997A (ja) |
DE (1) | DE69731646T2 (ja) |
ES (1) | ES2234016T3 (ja) |
GB (1) | GB9619002D0 (ja) |
WO (1) | WO1998010750A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021045A1 (ja) * | 2003-08-29 | 2005-03-10 | Anges Mg, Inc. | 針無注射器を用いた皮膚疾患の遺伝子治療 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7223739B1 (en) | 1995-06-07 | 2007-05-29 | Powderject Vaccines, Inc. | Adjuvanted genetic vaccines |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
CA2279204C (en) | 1997-01-30 | 2005-11-15 | Chiron Corporation | Use of microparticles with adsorbed antigen to stimulate immune responses |
US6884435B1 (en) | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
DE69925293T2 (de) | 1998-10-01 | 2006-01-26 | Powderject Research Ltd. | Sprühbeschichtete mikropartikel für nadellose spritzen |
US6881723B1 (en) | 1998-11-05 | 2005-04-19 | Powderject Vaccines, Inc. | Nucleic acid constructs |
BR0007974A (pt) * | 1999-02-03 | 2001-10-30 | Powderject Res Ltd | Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo |
US7022320B1 (en) | 1999-02-09 | 2006-04-04 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis immunization |
US7196066B1 (en) | 1999-11-03 | 2007-03-27 | Powderject Vaccines, Inc. | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
CA2420621C (en) | 2000-09-28 | 2011-05-24 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
GB0103620D0 (en) * | 2001-02-14 | 2001-03-28 | Prometic Biosciences Ltd | Sterile composition and its preparation |
JP5557415B2 (ja) | 2003-06-02 | 2014-07-23 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物 |
CA2702340C (en) | 2006-10-12 | 2014-12-16 | The University Of Queensland | Compositions and methods for modulating immune responses |
DE102007004855B4 (de) * | 2007-01-31 | 2014-03-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Vorrichtung und Verfahren zur Deposition von biologischem Material in einem Zielsubstrat |
CN101998965B (zh) | 2007-11-01 | 2014-03-12 | 安斯泰来制药有限公司 | 免疫抑制性多肽与核酸 |
WO2012058715A1 (en) | 2010-11-01 | 2012-05-10 | University Of Technology, Sydney | Immune-modulating agents and uses therefor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6707194A (en) * | 1993-04-19 | 1994-11-08 | Medisorb Technologies International L.P. | Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression |
GB9612629D0 (en) * | 1996-06-17 | 1996-08-21 | Oxford Biosciences Ltd | Method for providing dense particle compositions for use in transdermal particle delivery |
-
1996
- 1996-09-11 GB GBGB9619002.0A patent/GB9619002D0/en active Pending
-
1997
- 1997-09-11 AU AU43079/97A patent/AU4307997A/en not_active Abandoned
- 1997-09-11 ES ES97919142T patent/ES2234016T3/es not_active Expired - Lifetime
- 1997-09-11 JP JP10513388A patent/JP2001500858A/ja not_active Ceased
- 1997-09-11 DE DE69731646T patent/DE69731646T2/de not_active Expired - Fee Related
- 1997-09-11 EP EP97919142A patent/EP0928190B1/en not_active Expired - Lifetime
- 1997-09-11 WO PCT/GB1997/002478 patent/WO1998010750A2/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021045A1 (ja) * | 2003-08-29 | 2005-03-10 | Anges Mg, Inc. | 針無注射器を用いた皮膚疾患の遺伝子治療 |
JPWO2005021045A1 (ja) * | 2003-08-29 | 2006-10-26 | アンジェスMg株式会社 | 針無注射器を用いた皮膚疾患の遺伝子治療 |
Also Published As
Publication number | Publication date |
---|---|
EP0928190A2 (en) | 1999-07-14 |
DE69731646T2 (de) | 2005-12-01 |
EP0928190B1 (en) | 2004-11-17 |
DE69731646D1 (de) | 2004-12-23 |
GB9619002D0 (en) | 1996-10-23 |
WO1998010750A2 (en) | 1998-03-19 |
WO1998010750A3 (en) | 1998-06-25 |
ES2234016T3 (es) | 2005-06-16 |
AU4307997A (en) | 1998-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6893664B1 (en) | Particle delivery techniques | |
JP2001500858A (ja) | 核酸粒子の送達 | |
US6475779B2 (en) | Polymeric gene delivery | |
US20030166594A1 (en) | Nucleic acid delivery system | |
JP2000513338A (ja) | 経皮粒子送達に使用するための高密度化された粒子組成物を提供する方法 | |
JP2003528024A (ja) | 製剤化された核酸分子の無針注入 | |
MXPA06003978A (es) | Constructos de acidos nucleicos. | |
ZA200503380B (en) | Nucleic acid coated particles | |
WO1996027393A9 (en) | A dry powder formulation for gene therapy | |
EP0844004B1 (en) | Collagen containing gene preparations | |
Wang et al. | Poly (D, L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination | |
EP1200067B1 (en) | Method for the preparation of microparticles comprising biological material | |
JP2005500327A (ja) | 肝臓へのdnaのトランスフェクションの増強 | |
JP2002503709A (ja) | 遺伝子治療における治療用遺伝子のストレスプロモーターによる調節:その組成物及び方法 | |
EP1491215A1 (en) | Remedies with the use of hollow protein nanoparticles presenting growth factor or the like | |
AU782370B2 (en) | Nucleic acid delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040910 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040910 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071127 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080128 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080417 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080417 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080722 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081216 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090224 |